Abstract
Although heart failure is predominantly caused by cardiovascular conditions such as hypertension, coronary heart disease and valvular heart disease, it can also be caused by adverse drug reactions. Several medications have been shown to have cardiotoxic effects. Among those therapeutic agents, anti-inflammatory drugs, including exogenous glucocorticoids, nonsteroidal anti-inflammatory drugs and biologics, which are used to treat a broad range of diseases that are associated with inflammatory processes, are widely prescribed in clinical practice. In this review, we discuss insights from experimental models on the beneficial and cardiotoxic effects of anti-inflammatory drugs.
Keywords: Glucocorticoids, NSAIDs, biologics, heart failure, ischemia/reperfusion, cardiac hypertrophy, cardiotoxic drugs, experimental models
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Cardiac Consequences of Anti-Inflammatory Drugs in Experimental Models
Volume: 12 Issue: 1
Author(s): Nolwenn Merlet, David Busseuil, Eric Rheaume and Jean-Claude Tardif
Affiliation:
Keywords: Glucocorticoids, NSAIDs, biologics, heart failure, ischemia/reperfusion, cardiac hypertrophy, cardiotoxic drugs, experimental models
Abstract: Although heart failure is predominantly caused by cardiovascular conditions such as hypertension, coronary heart disease and valvular heart disease, it can also be caused by adverse drug reactions. Several medications have been shown to have cardiotoxic effects. Among those therapeutic agents, anti-inflammatory drugs, including exogenous glucocorticoids, nonsteroidal anti-inflammatory drugs and biologics, which are used to treat a broad range of diseases that are associated with inflammatory processes, are widely prescribed in clinical practice. In this review, we discuss insights from experimental models on the beneficial and cardiotoxic effects of anti-inflammatory drugs.
Export Options
About this article
Cite this article as:
Merlet Nolwenn, Busseuil David, Rheaume Eric and Tardif Jean-Claude, Cardiac Consequences of Anti-Inflammatory Drugs in Experimental Models, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2013; 12 (1) . https://dx.doi.org/10.2174/1871523011312010005
DOI https://dx.doi.org/10.2174/1871523011312010005 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metabolomics Reveals Hyperlipidemic Biomarkers and Antihyperlipidemic Effect of Poria cocos
Current Metabolomics The Brain-Immune-Gut Triangle: Innate Immunity in Psychiatric and Neurological Disorders
Current Immunology Reviews (Discontinued) PEGylation: An Overview and Recent Advances Reported in the Patent Literature
Recent Patents on Chemical Engineering Translational Application of Combining Magnetic Resonance Imaging and Biomechanical Analysis in Carotid Plaque Vulnerability Assessment
Recent Patents on Medical Imaging Influence of Gender on C-Reactive Protein, Fibrinogen, and Erythrocyte Sedimentation Rate in Obstructive Sleep Apnea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Relationship Between Hypertensive Retinopathy and Angiotensin Converting Enzyme Gene Polymorphism
Cardiovascular & Hematological Disorders-Drug Targets Macrophage Polarization as a Therapeutic Target in Myocardial Infarction
Current Drug Targets Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications
Current Pharmaceutical Design Semi-Quantitative Ultrasonographic Evaluation of NAFLD
Current Pharmaceutical Design Biological and Pharmacological Effects of Gamma-oryzanol: An Updated Review of the Molecular Mechanisms
Current Pharmaceutical Design The Role of Stem Cell Factor and Granulocyte-Colony Stimulating Factor in Treatment of Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Pulmonary Hypertension secondary to Left Heart Disease
Current Vascular Pharmacology Inorganic Nanoparticles for In Vitro Cancer Diagnosis: A Patent Review
Recent Patents on Nanomedicine Discovery of a Novel Anti-Cancer Agent Targeting Both Topoisomerase I & II as Well as Telomerase Activities in Human Lung Adenocarcinoma A549 Cells In Vitro and In Vivo: Cinnamomum verum Component Cuminaldehyde
Current Cancer Drug Targets Intracranial Collateral Flow Estimated by Color Velocity Imaging Quantification Ultrasound: A Protector of Recurrent Stroke in Patient with Carotid Stenosis?
Current Neurovascular Research Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Molecular Targets of Diabetic Vascular Complications and Potential New Drugs
Current Drug Targets